Phase-resolved Hubble Space Telescope ultraviolet spectroscopy

We present highly time-resolved HST FOS UV spectroscopy of the nova-like binary V795 Her. Several key results emerge. For the first time we find a strong 2.6-h signature in the variability of the UV lines. The HST data reveal no evidence of a 4.8-h ‘period’, in contrast to our previous IUE observations. This, and differences in the spectral line characteristics, suggests that HST found the system in a different state from earlier IUE observations. The C IV line alone contains a fairly stable, asymmetric, extended blueward absorption trough which we associate with a wind outflow. The 2.6-h variations of the line profiles are largely confined to an interval of about 0.4 in phase and to the velocity regime −1500 < v < 0 km s−1, the changes being dominated by the apparent decline and re-emergence of a blueshifted emission peak. The complex profiles permit many empirical interpretations, but the simplest attributes the variability to a narrow (FWHM∼1000 km s−1) emission component which is always blueshifted with a mean velocity of around –600 km s−1. This interpretation, however, is not readily related to any obvious source within the binary. An alternative picture, which attempts to relate the UV and (simultaneously observed) optical line behaviour, invokes a more stable, broad (FWHM∼2000 km s−1) emission feature, the intrinsic morphology of which is disguised by superposed constant and variable absorption components. One tentative physical explanation of such a decomposition involves an accretion stream that overflows the accretion disc. However, several problems with this model remain to be resolved. We also draw attention to similarities between the velocity-restricted behaviour in the UV lines of V795 Her and that in the optical lines of T Tauri stars. This might indicate a connection between V795 Her and the magnetically influenced inflow/outflow characteristics associated with the central star in T Tauri systems. If such a connection were eventually demonstrated, it would reopen the question of whether the 2.6-h period in V795 Her is really the binary period and whether the system is in fact related to the intermediate polars

Editorial: Horizons in Astronomy and Astrophysics

Editorial on the Research Topi

Internal Conditions of Accreting White Dwarfs

We explain the physics of compressional heating of the deep interior of an accreting white dwarf (WD) at accretion rates low enough so that the accumulated hydrogen burns unstably and initiates a classical nova (CN). In this limit, the WD core temperature (T_c) reaches an equilibrium value (T_c,eq) after accreting an amount of mass much less than the WD's mass. Once this equilibrium is reached, the compressional heating from within the envelope exits the surface. This equilibrium yields useful relations between the WD surface temperature, accretion rate and mass that can be employed to measure accretion rates from observed WD effective temperatures, thus testing binary evolution models for cataclysmic variables.Comment: 4 pages, 1 figure, uses CRCKAPB.sty (included); to appear in the `NATO Science Series II - Mathematics, Physics and Chemistry', Kluwer Academic Publisher

Editorial: Frontiers in astronomy and space sciences: Rising stars

Editorial on the Research Topic Frontiers in astronomy and space sciences: Rising star

A constitutive law for dense granular flows

A continuum description of granular flows would be of considerable help in predicting natural geophysical hazards or in designing industrial processes. However, the constitutive equations for dry granular flows, which govern how the material moves under shear, are still a matter of debate. One difficulty is that grains can behave like a solid (in a sand pile), a liquid (when poured from a silo) or a gas (when strongly agitated). For the two extreme regimes, constitutive equations have been proposed based on kinetic theory for collisional rapid flows, and soil mechanics for slow plastic flows. However, the intermediate dense regime, where the granular material flows like a liquid, still lacks a unified view and has motivated many studies over the past decade. The main characteristics of granular liquids are: a yield criterion (a critical shear stress below which flow is not possible) and a complex dependence on shear rate when flowing. In this sense, granular matter shares similarities with classical visco-plastic fluids such as Bingham fluids. Here we propose a new constitutive relation for dense granular flows, inspired by this analogy and recent numerical and experimental work. We then test our three-dimensional (3D) model through experiments on granular flows on a pile between rough sidewalls, in which a complex 3D flow pattern develops. We show that, without any fitting parameter, the model gives quantitative predictions for the flow shape and velocity profiles. Our results support the idea that a simple visco-plastic approach can quantitatively capture granular flow properties, and could serve as a basic tool for modelling more complex flows in geophysical or industrial applications.Comment: http://www.nature.com/nature/journal/v441/n7094/abs/nature04801.htm

Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure

The methotrexate (MTX) rescue agent carboxypeptidase G2 (CPDG2) rapidly hydrolyses MTX to the inactive metabolite DAMPA (4-[[2,4-diamino-6-(pteridinyl)methyl]-methylamino]-benzoic acid) and glutamate in patients with MTX-induced renal failure and delayed MTX excretion. DAMPA is thought to be an inactive metabolite of MTX because it is not an effective inhibitor of the MTX target enzyme dihydrofolate reductase. DAMPA is eliminated more rapidly than MTX in these patients, which suggests a nonrenal route of elimination. In a phase II study (May 1997–March 2002), CPDG2 was administered intravenously to 82 patients at a median dose of 50 U kg−1 (range 33–60 U kg−1). Eligible patients for this study had serum MTX concentrations of >10 μM at 36 h or >5 μM at 42 h after start of MTX infusion and documented renal failure (serum creatinine ⩾1.5 times the upper limit of normal). Immediately before CPDG2 administration, a median MTX serum level of 11.93 μM (range 0.52–901 μM) was documented. Carboxypeptidase G2 was given at a median of 52 h (range 25–178 h) following the start of an MTX infusion of 1–12 g m−2 4–36 h−1 and resulted in a rapid 97% (range 73–99%) reduction of the MTX serum level. Toxicity related to CPDG2 was not observed. Toxicity related to MTX was documented in about half the patients; four patients died despite CPDG2 administration due to severe myelosuppression and septic complications. In conclusion, administration of CPDG2 is a well-tolerated, safe and a very effective way of MTX elimination in delayed excretion due to renal failure

Experimental treatment of Ebola virus disease with brincidofovir

Background The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. Methods and Findings In this single-arm phase 2 trial conducted in Liberia, patients with laboratory-confirmed EVD (two months of age or older, enrolment bodyweight ≥50 kg) received oral brincidofovir 200 mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14. Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment. The primary outcome was survival at Day 14 after the first dose of brincidofovir. Four patients were enrolled between 01 January 2015 and 31 January 2015. The trial was stopped following the decision by the manufacturer to terminate their program of development of brincidofovir for EVD. No Serious Adverse Reactions or Suspected Unexpected Serious Adverse Reactions were identified. All enrolled subjects died of an illness consistent with EVD. Conclusions Due to the small sample size it was not possible to determine the efficacy of brincidofovir for the treatment of EVD. The premature termination of the trial highlights the need to establish better practices for preclinical in-vitro and animal screening of therapeutics for potentially emerging epidemic infectious diseases prior to their use in patients